GSK-3 and BCL-XL inhibition mitigates the competitive advantage of APC-mutant colorectal cancer cells

Abstract BCL-XL is a crucial anti-apoptotic protein that supports survival of intestinal cells during the progression and in established colorectal cancer (CRC). While targeting BCL-XL with BH3 mimetics is effective, its significant toxicity highlights the need for alternative approaches. Importantl...

Descripción completa

Detalles Bibliográficos

Autores principales:	Le Zhang, Lidia Atencia Taboada, Selami Baglamis, Maartje de Kroon, Carolien Elshout, Prashanthi Ramesh, Roxan F.C.P.A Helderman, Arezo Torang, Kate Cameron, Milou S. van Driel, Valérie M. Wouters, Sanne M. van Neerven, Jan Paul Medema
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Publishing Group 2025-07-01
Colección:	Oncogenesis
Acceso en línea:	https://doi.org/10.1038/s41389-025-00569-y
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!